Asset Details
Do you wish to reserve the book?
MAPK13 stabilization via m6A modification limits anti-cancer efficacy of rapamycin
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
MAPK13 stabilization via m6A modification limits anti-cancer efficacy of rapamycin
Do you wish to request the book?
MAPK13 stabilization via m6A modification limits anti-cancer efficacy of rapamycin
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Paper
MAPK13 stabilization via m6A modification limits anti-cancer efficacy of rapamycin
2022
Overview
N6-adenosine methylation (m6A) is the most abundant mRNA modification that controls gene expression through multiple diverse mechanisms. m6A-dependent regulation of oncogenes and tumor suppressors indeed contribute to tumor development. However, the role of m6A-mediated gene regulation after drug treatment or resistance is poorly understood. Here, we report that m6A modification of mitogen-activated protein kinase 13 (MAPK13) determines the sensitivity of cancer cells to the mechanistic target of rapamycin complex 1 (mTORC1) 1-targeting chemotherapeutic agent rapamycin. mTORC1 induces m6A modification of MAPK13 mRNA at its 3′ untranslated region (3′UTR) through methyltransferase-like 3 (METTL3)-METTL14-Wilms' tumor 1-associating protein (WTAP) methyltransferase complex, thereby stimulating its mRNA degradation via an m6A reader protein YTH domain family proteins 2 (YTHDF2). Rapamycin blunts this process and stabilizes MAPK13. Unexpectedly, MAPK13 silencing suppresses cell growth and enhances rapamycin′s anti-cancer effects, suggesting that MAPK13 is an oncogenic gene activated by rapamycin through negative feedback regulation. Together, our data indicate that rapamycin-mediated MAPK13 mRNA stabilization may confer drug resistance, and it can thus be a therapeutic target to sensitize cancer cells to rapamycin. Competing Interest Statement The authors have declared no competing interest. Footnotes * Nope.
